Speciality Medicines IPO Details: Price, Dates & Financials
The Speciality Medicines IPO GMP strength score is 8 out of 10, which the dashboard rates as Strong. The Speciality Medicines IPO valuation is tagged Strong. The Speciality Medicines IPO QIB category is reserved for 0.89% of the offer. The Speciality Medicines IPO NII/HNI category is reserved for 46.34% of the offer. The Speciality Medicines IPO Retail (RII) category is reserved for 46.38% of the offer. Live subscription numbers for the Speciality Medicines IPO are not yet available, and amounts are calculated at the upper price band of ₹124.
| Category | Sub (x) | Offered | Bid For |
|---|---|---|---|
| QIB | — | 21,000 (1%) | — |
| NII / HNI | — | 1,089,000 (46%) | — |
| Retail (RII) | — | 1,090,000 (46%) | — |
| Market Maker | — | 150,000 (6%) | — |
| Total | — | 2,350,000 (100%) | — |
* Amount calculated at upper price band (₹124) · ** Total includes all investor categories
- 1 Initiation of Refund 27 Mar 2026
- 2 Credit of Shares to Demat 27 Mar 2026
- Retail allocation is strong at 46% of the total offering.
- HNI/NII demand is strong at 46%.
- Institutional (QIB) interest is moderate at 1%.
- The IPO P/E of 10x reflects a strong valuation relative to typical market ranges.
- Pre-issue EPS of ₹13 compares to post-issue EPS of ₹12 after dilution.
This IPO shows strong fundamentals and healthy investor demand. Research the business model and compare with sector peers before applying.
GMP and IPO data are unofficial and for information only — not investment advice. Read the full disclaimer.